MasterMetabolicSwitch

One Mechanism, Many Diseases

Obesity, type-2 diabetes, fatty liver disease, and inflammatory bowel disorders are deeply interconnected. At a biological level, they share a common upstream driver: mitochondrial dysfunction and impaired cellular energy regulation. Yet most current therapies treat these conditions in isolation.

The HNF4α receptor - the master metabolic control switch - sits at the center of this disease network. Despite strong biological validation, no selective HNF4α agonist has reached clinical development - not because the target is weak, but because suitable molecules previously have been impossible to manufacture at scale.

From Nature to Molecule

From Natural Proof to Drug-Like Candiates

NCT provided the first compelling proof that selective HNF4α activation can drive meaningful metabolic effects. Building on this foundation, the eXoZymes platform enables the creation of new-to-nature analogs with improved potency, selectivity, and drug-like properties.

AI-supported enzyme engineering allows thousands of molecular variants to be explored rapidly. Crucially, the same cell-free system used for discovery is inherently compatible with scale-up, merging discovery, optimization, and manufacturability into a single workflow.

glp1

A Disciplined Path to Value Inflection

The pharmaceutical strategy is structured around clear, acquisition-relevant milestones. Early phases focus on composition-of-matter protection and lead optimization, followed by IND-enabling studies supported by scalable manufacturing from day one.

This aligns closely with current pharmaceutical acquisition behavior in metabolic disease, particularly as large players seek complementary mechanisms beyond GLP-1 agonists.

Want to be kept up to date?

We are excited to keep you updated with news tailored to your preferences. By subscribing to one or more streams, you'll receive information relevant to the areas you've selected. If you ever wish to update your preferences, you can do so at any time.